Materialise(MTLS) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, consolidated revenue grew by 6.8% year-on-year, reaching EUR 70.2 million, with a gross profit margin of 58.1% [15][16] - Adjusted EBIT for Q4 was EUR 4 million, representing a margin of 5.7%, and net profit was EUR 6.2 million, more than double the previous year's figure [15][27] - The net cash position improved to EUR 70.8 million, an increase of over EUR 3 million compared to the prior quarter [16][27] Business Line Data and Key Metrics Changes - Materialise Medical segment revenue increased by over 16% in Q4, accounting for 53% of consolidated revenue, while manufacturing revenue declined by 2% and software revenue stabilized with a slight decline of 1% [17][20] - For the full year 2025, medical revenue totaled EUR 134 million, manufacturing revenue was EUR 92.5 million, and software revenue was EUR 41 million [17][23] Market Data and Key Metrics Changes - The medical segment's strong performance was driven by a 23% increase in medical devices and services revenue [20] - The manufacturing segment faced macroeconomic headwinds, particularly in prototyping, leading to a 13% decline in annual revenue [24] Company Strategy and Development Direction - The company aims to continue investing in the Materialise Medical and Software segments while maintaining cost control in the Manufacturing segment [31] - A dual listing on Euronext Brussels was established to access a broader investor audience and enhance operational flexibility [5] Management's Comments on Operating Environment and Future Outlook - Management expects the Materialise Medical segment to continue growing at a double-digit pace, while the Manufacturing segment may face ongoing macroeconomic challenges [31] - The company anticipates revenue for 2026 to be in the range of EUR 273 million to EUR 283 million [31] Other Important Information - The company announced a share buyback program of up to EUR 30 million, which started on January 26, 2026 [5] - The deferred revenue balance for software maintenance and license fees increased by EUR 3.5 million in Q4, ending at EUR 48.8 million [18] Q&A Session Summary Question: Is manufacturing expected to be down year-over-year? - Management confirmed that manufacturing is expected to be flat to down due to a weaker industrial climate, particularly in Europe [36] Question: What percentage of manufacturing is for prototyping applications? - The company has not disclosed the exact percentage but acknowledged that prototyping remains a significant part of the business [39] Question: Can costs be reduced to achieve EBITDA breakeven in manufacturing? - Management indicated that they will continue to focus on segments with growth potential and work on cost optimization in the manufacturing segment [40] Question: Was there a one-time cost in Q4 OpEx? - Management noted that Q4 OpEx included non-recurring costs related to the Euronext listing, which should be excluded from baseline projections [41]